Ardi Pambuku

969 total citations · 1 hit paper
27 papers, 648 citations indexed

About

Ardi Pambuku is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Ardi Pambuku has authored 27 papers receiving a total of 648 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Genetics, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Ardi Pambuku's work include Glioma Diagnosis and Treatment (22 papers), Brain Metastases and Treatment (6 papers) and Radiomics and Machine Learning in Medical Imaging (5 papers). Ardi Pambuku is often cited by papers focused on Glioma Diagnosis and Treatment (22 papers), Brain Metastases and Treatment (6 papers) and Radiomics and Machine Learning in Medical Imaging (5 papers). Ardi Pambuku collaborates with scholars based in Italy, United Kingdom and United States. Ardi Pambuku's co-authors include Giuseppe Lombardi, Vittorina Zagonel, Luisa Bellu, Alessandro Della Puppa, Miriam Farina, Marina Paola Gardiman, Stefano Indraccolo, Eleonora Bergo, Domenico D’Avella and Alba A. Brandes and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Ardi Pambuku

26 papers receiving 644 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

2018 257 citations Giuseppe Lombardi, Gian Luca De Salvo et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ardi Pambuku Italy	11	451	190	174	167	130	27	648
Luisa Bellu Italy	13	465 1.0×	158 0.8×	162 0.9×	218 1.3×	128 1.0×	43	690
Myra E. van Linde Netherlands	14	365 0.8×	154 0.8×	219 1.3×	157 0.9×	188 1.4×	34	719
Kirsten Grunnet Denmark	14	494 1.1×	166 0.9×	151 0.9×	179 1.1×	76 0.6×	25	588
Eric Burton United States	14	404 0.9×	148 0.8×	207 1.2×	205 1.2×	186 1.4×	41	784
Scott Peak United States	7	438 1.0×	135 0.7×	131 0.8×	281 1.7×	209 1.6×	9	640
Alfred Yung United States	16	370 0.8×	150 0.8×	279 1.6×	179 1.1×	167 1.3×	29	672
Pietro Ciccarino Italy	12	453 1.0×	190 1.0×	168 1.0×	150 0.9×	74 0.6×	21	583
Kristin Alfaro-Munoz United States	11	410 0.9×	137 0.7×	129 0.7×	129 0.8×	87 0.7×	28	546
Marta Peñas-Prado United States	16	627 1.4×	174 0.9×	231 1.3×	264 1.6×	141 1.1×	68	861
Eva María Corrales-García Spain	7	375 0.8×	215 1.1×	270 1.6×	118 0.7×	88 0.7×	12	754

Countries citing papers authored by Ardi Pambuku

Since Specialization

Citations

This map shows the geographic impact of Ardi Pambuku's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ardi Pambuku with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ardi Pambuku more than expected).

Fields of papers citing papers by Ardi Pambuku

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ardi Pambuku. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ardi Pambuku. The network helps show where Ardi Pambuku may publish in the future.

Co-authorship network of co-authors of Ardi Pambuku

This figure shows the co-authorship network connecting the top 25 collaborators of Ardi Pambuku. A scholar is included among the top collaborators of Ardi Pambuku based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ardi Pambuku. Ardi Pambuku is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Galiano, Antonella, Ardi Pambuku, Sabina Murgioni, et al.. (2024). What do cancer patients experience of the simultaneous care clinic? Results of a cross‐sectional study on patient care satisfaction. Cancer Medicine. 13(3). e7000–e7000. 2 indexed citations

2.

Iannizzi, Pamela, Antonella Galiano, Ardi Pambuku, et al.. (2024). Psychological assessment and the role of the psychologist in early palliative care. Frontiers in Psychology. 15. 1437191–1437191.

3.

Ceccato, Filippo, Giuseppe Lombardi, Nora Albiger, et al.. (2019). Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor. Anti-Cancer Drugs. 30(5). 533–536. 8 indexed citations

4.

Indraccolo, Stefano, Giuseppe Lombardi, Matteo Fassan, et al.. (2018). Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma. Clinical Cancer Research. 25(6). 1828–1837. 82 indexed citations

5.

Lombardi, Giuseppe, Gian Luca De Salvo, Alba A. Brandes, et al.. (2018). Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet Oncology. 20(1). 110–119. 257 indexed citations breakdown →

6.

Lombardi, Giuseppe, Gian Luca De Salvo, Roberta Rudà, et al.. (2018). Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).. Journal of Clinical Oncology. 36(15_suppl). 2047–2047. 2 indexed citations

7.

Lombardi, Giuseppe, Mario Caccese, Luisa Bellu, et al.. (2018). Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment. Anti-Cancer Drugs. 29(9). 924–928. 1 indexed citations

8.

Lombardi, Giovanni, Eleonora Bergo, Luisa Bellu, et al.. (2018). P01.021 Comprehensive Geriatric Assessment (CGA) for outcome prediction in elderly patients (PTS)with glioblastoma (GBM): a mono-institutional experience. Neuro-Oncology. 20(suppl_3). iii232–iii233. 1 indexed citations

9.

Lombardi, Giuseppe, Luisa Bellu, Veronica Villani, et al.. (2018). A large, multicenter, retrospective study to identify a cutoff of MGMT methylation status by quantitative pyrosequencing approach in patients (PTS) with glioblastoma (GBM).. Journal of Clinical Oncology. 36(15_suppl). 2012–2012. 1 indexed citations

10.

Lombardi, Giuseppe, Gian Luca De Salvo, Alba A. Brandes, et al.. (2017). REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib activity in relapsed glioblastoma patients. Annals of Oncology. 28. v610–v610. 3 indexed citations

11.

Lombardi, Giuseppe, Ardi Pambuku, Margherita Lorusso, et al.. (2017). Activity of temozolomide (TMZ) in patients (PTS) with malignant pheochromocytoma or paraganglioma (MPP): A mono-institutional retrospective study. Annals of Oncology. 28. v156–v156. 1 indexed citations

12.

Lombardi, Giuseppe, Ardi Pambuku, Luisa Bellu, et al.. (2017). Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology. 111. 94–102. 70 indexed citations

13.

Ferrara, Alfonso Massimiliano, Giuseppe Lombardi, Ardi Pambuku, et al.. (2017). Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma. Anti-Cancer Drugs. 29(1). 102–105. 13 indexed citations

14.

Lombardi, Giuseppe, Luisa Bellu, Ardi Pambuku, et al.. (2016). Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study. Journal of Neuro-Oncology. 128(3). 481–486. 10 indexed citations

15.

Pambuku, Ardi, Giuseppe Lombardi, Roberta Bertorelle, et al.. (2016). MGMT promoter methylation status in glioblastoma (GBM) patients: a quantitative pyrosequencing approach and its prognostic role. Annals of Oncology. 27. vi107–vi107. 2 indexed citations

16.

Pambuku, Ardi, Giuseppe Lombardi, Roberta Bertorelle, et al.. (2016). MGMT promoter methylation status in glioblastoma (GBM) patients: a quantitative pyrosequencing approach and its prognostic role. Annals of Oncology. 27. iv114–iv114. 1 indexed citations

17.

Lombardi, Giuseppe, Sara Lonardi, Ardi Pambuku, et al.. (2015). Hepatocellular carcinoma in elderly patients: a concise review on systemic therapy with sorafenib. Hepatoma Research. 1(2). 58–58. 1 indexed citations

18.

Lombardi, Giuseppe, Giuseppe Corona, Patrizia Farina, et al.. (2014). Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with IDH-mutated glioma.. Journal of Clinical Oncology. 32(15_suppl). 2037–2037. 1 indexed citations

19.

Lombardi, Giuseppe, Patrizia Farina, Alessandro Della Puppa, et al.. (2014). An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab. BioMed Research International. 2014. 1–8. 13 indexed citations

20.

Lombardi, Giuseppe, Ardi Pambuku, Luisa Bellu, et al.. (2013). Cisplatin and Temozolomide Combination in the Treatment of Supratentorial Anaplastic Ependymoma. Chemotherapy. 59(3). 176–180. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact